Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, announced today that the Japanese Patent Office has decided to grant the Company a new key patent, covering the use of its lead stem cell technology Progenza™ to treat pain, through to 2032.
DISC: I don't hold but do hold OCC